Loo H, Scatton B, Poirier M F, Benkelfat C, Dennis T, Vanelle J M, Garreau M, Sechter D
Presse Med. 1985 Jun 22;14(25):1363-6.
Dihydroxy-phenyl-ethylene-glycol (DOPEG or DHPG), a deaminated catabolite of noradrenaline formed after presynaptic re-uptake, is a good marker of metabolic activity in noradrenergic pathways. Plasma levels of free, conjugated and total DOPEG were measured by a radioenzymatic method in 45 patients with major depression selected according to the DSM 3 criteria and in 45 matched controls. A significant decrease in man DOPEG levels was observed in all depressive patients. A dexamethasone suppression test performed in these patients showed no difference in DOPEG levels between responders and non-responders, thus failing to support the hypothesis that subjects with low noradrenergic drive escape suppression. There was no correlation between plasma DOPEG levels and urinary excretion of methoxy-hydroxy-phenylglycol (MOPEG), another marker of noradrenaline metabolic activity. Thirty-one patients were treated with a specific monoaminergic antidepressant: maprotiline or indalpine; contrary to urinary MOPEG levels, plasma DOPEG levels had no predictive value concerning the response to this category of antidepressants. The various possible reasons for the fall in DOPEG observed in depressive patients are discussed.
二羟基苯乙二醇(DOPEG或DHPG)是去甲肾上腺素在突触前再摄取后形成的一种脱氨基分解代谢产物,是去甲肾上腺素能通路代谢活性的良好标志物。采用放射酶法测定了45例根据DSM-Ⅲ标准选取的重度抑郁症患者及45例匹配对照者的游离、结合及总DOPEG的血浆水平。在所有抑郁症患者中均观察到DOPEG水平显著降低。对这些患者进行的地塞米松抑制试验显示,反应者与无反应者的DOPEG水平无差异,因此未能支持低去甲肾上腺素能驱动的受试者逃避抑制这一假说。血浆DOPEG水平与去甲肾上腺素代谢活性的另一个标志物甲氧基羟基苯乙二醇(MOPEG)的尿排泄之间无相关性。31例患者接受了一种特异性单胺能抗抑郁药治疗:马普替林或吲哚平;与尿MOPEG水平不同,血浆DOPEG水平对这类抗抑郁药的反应无预测价值。文中讨论了抑郁症患者中观察到的DOPEG降低的各种可能原因。